12 research outputs found
Diagnosis and treatment of early esophageal carcinoma and second primary tumors in the upper aerodigestive tract
This thesis aims to provide insights in the incidence and risk of second and multiple primary tumors (MPTs) in the upper aerodigestive tract (UADT) in patients with esophageal squamous cell carcinoma (ESCC) and in patients with head and neck squamous cell carcinoma (HNSCC).
The second aim of this thesis is to investigate whether screening for these MPTs should be recommended.
The third aim of this thesis is to optimize clinical staging and endoscopic resection (ER) of early esophageal cancer (EC) and to develop a prediction model that estimates the risk of lymph node metastases (LNM) in individual patients with submucosal (pT1b) esophageal adenocarcinoma (EAC)
Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: A systematic review and meta-analysis
Background: Esophageal squamous cell carcinomas (ESCCs) are often accompanied by head and neck second primary
tumors (HNSPTs). The prognosis of patients with an additional HNSPT is worse compared with patients with only ESCC.
Therefore, early detection of HNSPTs may improve the overall outcome of patients with ESCC.
The purpose of this study was to investigate the yield of endoscopic screening for HNSPTs in patients with primary ESCC.
Methods: We conducted a systematic literature search of all available databases. Studies were included if ESCC patients
were endoscopically screened for HNSPT. The primary outcome was the pooled prevalence of HNSPTs.
Results: Twelve studies, all performed in Japan, were included in this systematic review with a total of 6483 patients.
The pooled prevalence of HNSPTs was 6.7% (95% confidence interval: 4.9–8.4). The overall heterogeneity was high
across the studies (I
2
¼ 89.0%, p < 0.001). Most HNSPTs were low stage (85.3%) and located in the hypopharynx
(60.3%). The proportion of synchronous (48.2%) and metachronous (51.8%) HNSPTs was comparable.
Conclusion: Based on our results, HNSPT screening could be considered in patients with primary ESCC. All studies were
performed in Japan; it is therefore not clear whether this consideration applies to the Western world
Effectiveness of topical budesonide in preventing esophageal strictures after endoscopic resection of esophageal cancer
Background and study aims A disadvantage of endoscopic resection (ER) of early esophageal cancer (EC) is the high stricture rate after resection. A risk factor for stricture development is a mucosal defect after ER of ≥ 75 % of the esophageal circumference. Stricture rates up to 94 % have been reported in these patients. The aim of this stu
Propofol sedation without endotracheal intubation is safe for endoscopic submucosal dissection in the esophagus and stomach
Background: Endoscopic submucosal dissection (ESD) for early esophageal and stomach cancer is usually performed under
general anesthesia. However, propofol sedation without endotracheal intubation has been suggested as a viable alternative.
Objective: The objective of this study was to evaluate the safety of propofol sedation without endotracheal intubation during
ESD in the upper gastrointestinal tract.
Methods: We performed a retrospective cohort study of patients who underwent ESD for upper gastrointestinal tumors with
propofol-remifentanil analgosedation in a tertiary referral center in the Netherlands between
Early detection of esophageal second primary tumors using Lugol chromoendoscopy in patients with head and neck cancer: A systematic review and meta-analysis
Background: Early detection of esophageal secondary primary tumors (SPTs) in
head and neck squamous cell carcinoma (HNSCC) patients could increase patient
survival. The purpose of this study was to determine the diagnostic yield of esophageal SPTs using Lugol chromoendoscopy.
Methods: A systematic review of all available databases was performed to find all
Lugol chromoendoscopy screening studies.
Results: Fifteen studies with a total of 3386 patients were included. The average
yield of esophageal-SPTs in patients with HNSCC was 15%. The prevalence was
the highest for patients with an index hypopharyngeal (28%) or oropharyngeal
(14%) tumor. The esophageal-SPTs were classified as high-grade dysplasia in 49%
of the cases and as invasive carcinoma's in 51%.
Conclusion: Our results show that 15% of the patients with HNSCC that underwent Lugol chromoendoscopy were diagnosed with an esophageal-SPT. Based on
these results there is enough evidence to perform Lugol chromoendoscopy, especially in an Asian patient population
Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: A nationwide study in a Western population
Background: Patients with primary oesophageal squamous cell carcinoma are at risk of developing multiple primary tumours in the upper aero digestive tract. To date, most studies are performed in the Asian population. We aimed to evaluate the risk of multiple primary tumours in the upper aero digestive tract and stomach in patients with oesophageal squamous cell carcinoma in a Western population. Methods: We performed a nationwide, retrospective cohort study in collaboration with the Netherlands Cancer Registry. Patients with primary oesophageal squamous cell carcinoma, diagnosed between 2000–2016, were included. Primary endpoints were synchronous and metachronous multiple primary tumour risk. Results: The cohort consisted of 9058 patients, diagnosed with oesophageal squamous cell carcinoma (male: 57.3%, median age 67 years). In 476 patients (5.3%), 545 multiple primary tumours have been diagnosed. Most of them were located in the head and neck region (49.5%). Among all multiple primary tumours, 329 (60.4%) were diagnosed synchronously (<6 months after oesophageal squamous cell carcinoma diagnosis) and 216 (39.6%) metachronously (≥6 months). Patients with oesophageal squamous cell carcinoma had a significantly increased risk of both synchronous (standardised incidence ratio 10.95, 99% confidence interval 9.40–12.53) and metachronous multiple primary tumours (standardised incidence ratio 4.36, 99% confidence interval 3.56–5.10), compared to the general population. The median interval to metachronous second primary tumour diagnosis was 3.0 years (interquartile range 1.8–5.9). Conclusion: Approximately one in 20 patients with primary oesophageal squamous cell carcinoma have a second primary tumour in the upper aero digestive tract or stomach, either at the time of oesophageal squamous cell carcinoma diagnosis or at a later stage. As second primary tumours occur at an increased risk compared to the ge
Periprocedural adverse events after endoscopic resection of T1 colorectal carcinomas
Cellular mechanisms in basic and clinical gastroenterology and hepatolog
Propofol sedation without endotracheal intubation is safe for endoscopic submucosal dissection in the esophagus and stomach
Background: Endoscopic submucosal dissection (ESD) for early esophageal and stomach cancer is usually performed under
general anesthesia. However, propofol sedation without endotracheal intubation has been suggested as a viable alternative.
Objective: The objective of this study was to evaluate the safety of propofol sedation without endotracheal intubation during
ESD in the upper gastrointestinal tract.
Methods: We performed a retrospective cohort study of patients who underwent ESD for upper gastrointestinal tumors with
propofol-remifentanil analgosedation in a tertiary referral center in the Netherlands between
Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors.
Contains fulltext :
220104pub.pdf (publisher's version ) (Open Access)BACKGROUND: Inflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients is increased. The relation between IBD patients and laryngeal cancer (LC) remains unclear. We aimed (1) to identify risk factors in IBD patients for LC development and (2) to compare clinical characteristics, outcome, and survival of LC in IBD patients with the general population. METHODS: All IBD patients with LC (1993-2011) were retrospectively identified using the Dutch Pathology Database. We performed 2 case-control studies: (1) to identify risk factors, we compared patients with IBD and LC (cases) with the general IBD population; (2) to analyze LC survival, we compared cases with controls from the general LC population. RESULTS: We included 55 cases, 1800 IBD controls, and 2018 LC controls. Cases were more frequently male compared with IBD controls (P < 0.001). For ulcerative colitis (UC), cases were older at IBD diagnosis (P < 0.001). Crohn's disease (CD) cases were more frequently tobacco users (P < 0.001) and more often had stricturing (P = 0.006) and penetrating (P = 0.008) disease. We found no survival difference. Immunosuppressive medication had no impact on survival. CONCLUSIONS: Male sex was a risk factor for LC in IBD patients. Older age at IBD diagnosis was a risk factor for UC to develop LC. Tobacco use and stricturing and penetrating disease were risk factors for LC development in CD patients. Inflammatory bowel disease was not associated with impaired survival of LC. Immunosuppressive medication had no influence on survival